Sponsor · Operator · Inspector view

Studies Portfolio

6 studies · 5 active · 3 at-risk

One row per study, scannable at a glance: sponsor, phase, KPIs, timeline, risks, resources. Click into a card for the full sit-rep, milestone Gantt, and regulator-grade provenance trail.

← Home Inspection view Staging review

Platform Activity

UTC days · provenance events

Last 90 days: 0 events across 0 active days · Current streak: 0 days

LessMore

WatchONC-002
Acme Therapeutics
Relapsed/refractory multiple myeloma
Phase 2bEnrollingOncology
Single-arm dose-expansion of acemyebrelin in r/r multiple myeloma. Enrolment is tracking 12% behind plan due to slow activation at two EU sites; mitigation underway with two new US sites in start-up.
Enrolment
88 / 120 (73%)
-12% vs plan
Screen failure rate
34%
+4 pts
Query aging (>14d)
47 open
+8
Timeline
Sep 2024forecast Jun 2027
Risks
1 high2 medium
Resources
9.6 FTE · 14 HC
Live activity
No activity recorded yetNo activity yet
View details →Sponsor view
At riskRARE-007
Northwind Genetics
X-linked hypophosphatemia in adults
Phase 3EnrollingRare disease
Pivotal Ph3 placebo-controlled study. Enrolment is critically behind (41% vs 65% planned) and a Type B FDA meeting is scheduled to discuss sample-size re-estimation. EAC has breached the contracted budget.
Enrolment
74 / 180 (41%)
-24% vs plan
Screen failure rate
52%
+11 pts
Query aging (>14d)
92 open
+31
Timeline
Mar 2024forecast Aug 2028
Risks
1 critical2 high1 medium
Resources
19.1 FTE · 25 HC
Live activity
No activity recorded yetNo activity yet
View details →Sponsor view
On trackDERM-003
Lyra Skin Sciences
Moderate-to-severe atopic dermatitis (combination device)
Phase 2aEnrollingDermatology / Device
Combination device + topical study in atopic dermatitis. Enrolment is 4 weeks ahead of plan, all KPIs are within tolerance, and DBL is forecast on time.
Enrolment
96 / 120 (80%)
+6% vs plan
Screen failure rate
21%
-2 pts
Query aging (>14d)
8 open
-3
Timeline
Nov 2024forecast Apr 2027
Risks
1 medium1 low
Resources
5.4 FTE · 8 HC
Live activity
No activity recorded yetNo activity yet
View details →Sponsor view
On trackCV-118
Helios Cardio
Reduction of MACE in post-MI patients with elevated Lp(a)
Phase 3Follow-upCardiovascular
Event-driven CV outcomes Ph3. All randomisation complete; in long-term follow-up. Event accrual is on plan and interim analysis 2 closed with DSMB recommendation to continue unchanged.
Enrolment
8,400 / 8,400 (100%)
complete
Screen failure rate
28%
final
Query aging (>14d)
34 open
-9
Timeline
May 2021forecast Jul 2027
Risks
1 medium2 low
Resources
30.1 FTE · 47 HC
Live activity
No activity recorded yetNo activity yet
View details →Sponsor view
WatchVAX-014
Stellis Vaccines
Respiratory syncytial virus in older adults
Phase 2bEnrollingVaccines / Infectious disease
Adjuvanted RSV vaccine Ph2b dose-finding. Enrolment on plan, but a manufacturing lot deviation triggered a 6-week pause to re-qualify; recovery plan in place.
Enrolment
420 / 600 (70%)
+1% vs plan
Screen failure rate
14%
+2 pts
Query aging (>14d)
29 open
+11
Timeline
Dec 2024forecast Dec 2027
Risks
1 high1 medium1 low
Resources
13.0 FTE · 19 HC
Live activity
No activity recorded yetNo activity yet
View details →Sponsor view